Back to News
Market Impact: 0.18
Jaguar Health Receives Fee Waivers from FDA
Source: Newswire
Healthcare & BiotechCorporate Guidance & OutlookProduct Launches
The company reaffirmed its focus on global development of crofelemer powder for oral solution in rare intestinal-failure indications, including microvillus inclusion disease (MVID) and short bowel syndrome (SBS). It is targeting a mid-2027 New Drug Application filing for MVID, providing a long-dated regulatory-development milestone but no new clinical or financial data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
More News
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- A ‘geologic freak’ called the Smackover may end America’s lithium dependence on China, and Big Oil is already there
- Investing in Prediction Markets Will Pay Off, DraftKings CEO Says
- Where's the growth? Legacy automakers face a tougher 2027 as costs rise, market tightens
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction